Themis Medicare Reports Q2 FY27 Financial Turnaround Driven by API Rebound
Themis Medicare Ltd · Investor Presentation · 16 Nov 2026, 12:52 am
Themis Medicare Reports Q2 FY27 Financial Turnaround Driven by API Rebound Themis Medicare reported net revenue of ₹89.74 crore for Q2 FY27, up 15.1% YoY, driven by a 71% rebound in its API segment to ₹20 crore and steady formulations revenue of ₹69 crore. The company turned operationally profitable with EBITDA reaching ₹5.58 crore (6.22% margin) and PAT of ₹7.06 crore (7.86% margin), against losses in Q2 FY26. For H1 FY27, revenue reached ₹176.70 crore and PAT stood at ₹31.67 crore. Hospital business drove 47% of Q2 revenue, alongside expansion plans in RoW and regulated markets.
Original exchange filing (PDF)
More announcements from Themis Medicare Ltd
- Themis Medicare Limited has submitted to the Exchange, the un-audited standalone & consolidated financial results for the quarter and half year ended September 30, 2026. · 14 Nov 2026
- Kindly refer to the Un-audited standalone and consolidated financial results for the quarter and half year ended 30.09.2026 · 14 Nov 2026
- Kindly refer to the Outcome of the Board Meeting held on 14.11.2026 · 14 Nov 2026
- Themis Medicare Limited has informed the Exchange about Board Meeting to be held on 14-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . · 14 Nov 2026
- THEMISMED : 14-Nov-2026 : The Company has informed the Exchange that a Board meeting to be held on November 05, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on November 14, 2026, To consider and approve the un-audited standalone & consolidated financial results for the period ended September 30, 2026 · 14 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CTL Trusteeship Ltd · 30 Oct 2026
- The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on October .... · 29 Oct 2026
- The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 28, 2026 for Vividhmargi Investments Pvt Ltd · 29 Oct 2026
